[go: up one dir, main page]

Rushe, 2022 - Google Patents

Engineered soluble protein C pathway receptors as novel pro-haemostatic agents

Rushe, 2022

View PDF
Document ID
5588429296076876119
Author
Rushe H
Publication year

External Links

Snippet

Haemophilia is a serious bleeding disorder caused by a deficiency in the components of the intrinsic tenase complex. Prophylactic replacement of the missing clotting factor is the current treatment for haemophilia, yet there remains a significant risk of inhibitor …
Continue reading at repository.rcsi.com (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

Similar Documents

Publication Publication Date Title
US10801019B1 (en) Engineered DNase enzymes and use in therapy
US7250168B2 (en) Tissue factor targeted thrombomodulin fusion proteins as anticoagulants
CN105992771B (en) The serpin of modification for hemorrhagic disease treatment
US10106786B2 (en) Compositions and methods for modulating hemostasis
AU2017267047A1 (en) Glycosylated VWF fusion proteins with improved pharmacokinetics
CN104271151A (en) NC-1-containing proteins for the treatment of angiogenesis-related diseases
JP5345069B2 (en) Preparation and use of low hemorrhagic anticoagulant fusion protein
JP2023532726A (en) ANTI-PROTEIN S SINGLE DOMAIN ANTIBODY AND POLYPEPTIDE CONTAINING THE SAME
Rushe Engineered soluble protein C pathway receptors as novel pro-haemostatic agents
US20220041716A1 (en) Fusion protein of single domain antibody and procoagulant
KR20230038658A (en) ADAMTS13 protein variants and uses thereof
US10208097B2 (en) Method for treating vascular stenosis or occlusive disease due to thrombi by administering a saxatilin-fc fusion protein
EP3370757B1 (en) Angiopoietins for use in promoting blood coagulation and in the treatment of blood coagulation disorders
CA2928762A1 (en) Compositions and methods for increasing the half-life of factor xa
Willis Fox Modulating cytoprotective signalling with engineered coagulation proteases
Maat Natural pathways for factor XII activation: Implications for hereditary angioedema
Le Quellec When engineering new recombinant factor IX molecules meets gene therapy: improvement of factor IX plasma level in patients with haemophilia B?